This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The daily use of cannabis by patients with chronic pain conditions is associated with prolonged improvements in pain management and subjects’ overall quality of life, as well as sustained reductions in the use of opioids, according to longitudinal data published in the journal Pain Medicine. ’
The administration of herbal cannabis is safe and effective in patients diagnosed with fibromyalgia, according to clinical data published this month in the Journal of Clinical Medicine. Israeli investigators assessed the use of cannabis over a six-month period in 211 patients with the disease.
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
The 144-page report, compiled by the Cannabis Regulation Oversight Office (CROO), incorporates data from several state departments. For each condition under consideration, a vote was taken to determine if the Board would make a recommendation to the IDPH Director to approve the condition for addition to the list of qualifying conditions.
The call for comments, posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”
Advantages and disadvantages Traditional topicals including water-based lotions and creams and oil-based balms and salves offer a quick onset time, no psychoactivity, and the potential to treat not only aches, pains, and inflammation, but also skin conditions like psoriasis and eczema. A killer app for pain?
Patients suffering from persistent pain conditions who frequently use cannabis are far less likely to use non-prescription opioids, according to longitudinal data published in the journal PLOS One.
The 144-page report, compiled by the Cannabis Regulation Oversight Office (CROO), incorporates data from several state departments. IDFPR FY2025 goals include: Continue working with CROO and the legislature to pass legislation to expand access to cannabis for medical patients. Find detailed information about this topic here.)
Those suffering from chronic pain report significant improvements in health following the passage of medical cannabis access laws, according to data published in the journal Forum for Health Economics & Policy. Among state-licensed medical cannabis registrants, two out of three report consuming cannabis to mitigate pain conditions.
Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. Sixty-six patients participated in the study. Half of the participants received dronabinol and the other half did not.
The Illinois Department of Public Health (IDPH), after confirming votes from the Medical Cannabis Advisory Board (MCAB), officially added four new conditions to the list of qualifying debilitating condition for Illinois patients in the Compassionate Use of Medical Cannabis Program.
The agency’s call for comments, initially posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”
Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Advantages of Data, Macro, and Micro. RYAH Group Inc.
MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.
In nursing school, I wrote my dissertation on the role of the nurse when caring for patients using cannabis therapeutically, knowing that nurses are often the first healthcare professional to whom patients disclose their cannabis use. I remain in awe of these patients to this day.
Medical cannabis is more popular than ever before, with 38 states having legalized some form of it for various health conditions. million patients in 2022, a sharp increase from the 3.1 million patients in 2022, a sharp increase from the 3.1 This data aligns with Americans’ rising acceptance of cannabis.
Follow strict patient verification and dispensing rules. Under the Therapeutic Goods Act and respective State/Territory guidelines, advertising medicinal cannabis directly to patients can violate advertising laws. The conditions of the relevant licenses and permits. Data Privacy 29. Competition Law 30.
Virginia has been one of the most reluctant states to consider marijuana law reform, though it recently began allowing some forms of cannabis oil for approved patients. And, 2019’s SB 1557 makes it possible for patients to get as much as 10mg of THC in each dose — the same limit as one serving size for edibles in adult-use states.
One gastrointestinal condition long associated with self-medication through cannabis is inflammatory bowel disease (IBD). In a newly published survey of 162 IBD patients in Puerto Rico, where medical cannabis is legal but recreational use is punishable with prison time , about 25% anonymously reported using cannabis to treat their symptoms.
NORML has previously written on the data showing a multi-directional association between cannabis and psychiatric illnesses, and we have cautioned that those predisposed to psychosis or other disorders may be at higher risk for adverse events. But it is not evidence that marijuana in any way causes the condition.
Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. Anonymized data also helps scientists better understand the cannabis plant and what products and chemical profiles are most effective for treating different conditions and symptoms.
A study published earlier this year reveals a simple but interesting pattern: When patients with ADHD consume more cannabis, they require fewer prescription drugs. According to the study’s research team , patients who consume medical marijuana report a “higher occurrence of stopping all ADHD medications.” Get Started.
According to a recent study published in the Journal of Headache Pain , across 2,032 patients and 21 illnesses, headache was a symptom treated with cannabis in 24.9% (505) of cases, while 88% (445) of headache patients treated probable migraines with cannabis. 30 percent of migraine patients in the U.S. The results?
New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).
Published in Nature , the study found that just under a third of patients report significant improvements and over half report moderate improvements while using CBD -rich oil derived from cannabis (30% CBD , 1-2% THC ). Endometriosis is a poorly-understood condition causing severe chronic pain and alterations in a woman’s menstrual cycle.
1 When we invited Cannigma readers to try Slumber’s Deep Zzzs gummies for sleep, we were particularly interested in digging into the data on sleep quality – not just total sleep time. 2 While the data collection effort did not include a control group, the prime findings were found to be statistically significant.
In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.
On top of recognizing the vast scope of benefits cannabis can provide, patients are saving lots of hard-earned money by swapping their pills for cannabis. The team that conducted the study looked at stock return and prescription drug sales data for 556 pharmaceutical companies. Why Patients Are Choosing MMJ Over Pharmaceuticals.
Instead of directly surveying the young patients, they reached out to their caregivers – the individuals who deeply understand the daily routines, challenges, and treatments of these children. This paves the way for a more integrated approach to care where CBD can be used alongside traditional treatments to optimize patient outcomes.
Of the 1,276 participants, 524 adult patients and 284 adult caregivers of children or dependent adults, all self-reported using cannabis for medicinal purposes. The control group consisted of 271 adult patients who were considering cannabis use, and 197 adult caregivers who were considering it for a dependent child or adult patient.
In these three dozen states, from the West Coast to the Midwest to the South and the Northeast, patients use cannabis to treat countless medical conditions and everyday ailments. of patients reported chronic pain as their primary condition, while in Connecticut 70.4% The most common medical conditions.
His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz and colleagues have published a paper summarizing ORR data from individuals with epilepsy in the medical journal Epilepsy & Behavior. About Realm of Caring.
THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.
Patients who suffer from epilepsy , which affects some 3.4 Pharmaceutical CBD is currently a restricted prescription medication, and insurance coverage is often limited to only those patients with the specific approved indications. Researchers Analyzed Survey Results from 280 Epilepsy Patients.
This efficacy translates to better medicine and better treatments for patients. When terpenes and cannabinoids interact together, there is a heightened efficacy for medical marijuana patients. This means that as a team these compounds make cannabis stronger and more efficient. Over 100 cannabis-based Terpenes have been discovered.
Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. “Available data strongly support the use of cannabinoids in treating fibromyalgia pain” due to “overwhelmingly positive treatment results.”
Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.
But newer research, including from this year, has indicated that cannabinoid suppositories do have clinical utility, and real-world data collected recently from Cannigma users shows that a CBD product based on a full extract cannabis oil (FECO) can significantly improve menstrual symptoms. And she got what she was looking for!
Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Data Bridge sees strong psychedelics growth.
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.
She was upset with herself for being so careless and concerned that the condition would persist. For many other people of all ages, tinnitus is indeed a chronic condition that has nothing to do with loud ‘80s cover bands in small clubs. And it’s not just ringing.
The study’s data showed that “Cannabis significantly reduced ratings of depression, anxiety, and stress.” Participants in the study recorded their personal experience when using cannabis for their depression and other mental conditions such as anxiety and stress; scientists were able to use data collected from the app to analyze the results.
16, 2020, but a report released earlier this month revealed the extent to which licensed patients were lined up for access. The Missouri Department of Health and Senior Services (DHSS) issued 56,448 new patient licenses and 12,062 renewed patient licenses between Dec. Psychiatric disorders accounted for 11,914 patients.
They announced that they’re ‘committed to ongoing transparency and will release additional datasets in the future’, such as data on Authorised Prescriber applications and the concentrations of active ingredients. Cannabis is currently used to treat a wide range of conditions.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content